18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer
暂无分享,去创建一个
Dimitris Visvikis | Mathieu Hatt | Nicolas Aide | Charline Lasnon | M. Hatt | D. Visvikis | M. Majdoub | N. Aide | C. Lasnon | P. Dô | B. Lavigne | J. Madelaine | Mohamed Majdoub | Brice Lavigne | Pascal Do | Jeannick Madelaine
[1] Ronald Boellaard,et al. Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation , 2016, Molecular Imaging and Biology.
[2] F. Gleeson,et al. Phantom and Clinical Evaluation of the Bayesian Penalized Likelihood Reconstruction Algorithm Q.Clear on an LYSO PET/CT System , 2015, The Journal of Nuclear Medicine.
[3] M. Hatt,et al. Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.
[4] R. Boellaard. Methodological aspects of multicenter studies with quantitative PET. , 2011, Methods in molecular biology.
[5] Dong Soo Lee,et al. Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result , 2014, Nuclear Medicine and Molecular Imaging.
[6] P. Christian,et al. PET/CT scanner validation for clinical trials-reasons for failure, recipes for success: the Clinical Trials Network (CTN) experience. , 2015 .
[7] Sébastien Jodogne,et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Osama Mawlawi,et al. Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. , 2016, Radiology.
[9] M. Lozano,et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[10] Y. D'Asseler,et al. Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[11] C. Chu,et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[12] M. Hatt,et al. 18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort , 2015, The Journal of Nuclear Medicine.
[13] Ronald Boellaard,et al. Mutatis Mutandis: Harmonize the Standard! , 2012, The Journal of Nuclear Medicine.
[14] Bernd J. Pichler,et al. Image-derived biomarkers and multimodal imaging strategies for lung cancer management , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Zhi-pei Liang,et al. Introduction to biomedical imaging , 2008 .
[16] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Dimitris Visvikis,et al. Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.
[18] Christian Roux,et al. A Fuzzy Locally Adaptive Bayesian Segmentation Approach for Volume Determination in PET , 2009, IEEE Transactions on Medical Imaging.
[19] P. Christian,et al. Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom , 2015, The Journal of Nuclear Medicine.
[20] Pierre Vera,et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2) , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[21] Florent Tixier,et al. The age of reason for FDG PET image-derived indices , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Ronald Boellaard,et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. Hatt,et al. Do clinical , histological or immunohistochemical primary tumor characteristics translate into different 18 FDG-PET / CT volumetric and heterogeneity features in stage II-III breast cancer ? , 2015 .
[24] Issam El-Naqa,et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes , 2009, Pattern Recognit..
[25] Nicolas Aide,et al. Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[26] Dimitris Visvikis,et al. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[27] R. Boellaard. Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.
[28] R. Jeraj,et al. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters , 2010, Acta oncologica.
[29] Dimitris Visvikis,et al. PET functional volume delineation: a robustness and repeatability study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[30] Dimitris Visvikis,et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. , 2010, International journal of radiation oncology, biology, physics.
[31] D. Townsend,et al. Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET , 2015, The Journal of Nuclear Medicine.
[32] R. Modzelewski,et al. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[33] D. Binns,et al. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[34] S. Swisher,et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[35] C. Chung. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[36] N. Aide,et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Fei Yang,et al. Quantitative radiomics: impact of stochastic effects on textural feature analysis implies the need for standards , 2015, Journal of medical imaging.
[38] Paul Kinahan,et al. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[39] Vladimir Y. Panin,et al. Fully 3-D PET reconstruction with system matrix derived from point source measurements , 2006, IEEE Transactions on Medical Imaging.
[40] M. Hatt,et al. Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[41] Thomas Beyer,et al. High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[42] El Naqa,et al. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities , 2015 .